Janus Henderson Group PLC Bio Atla, Inc. Transaction History

Janus Henderson Group PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$6.29 - $11.01 $1.21 Million - $2.11 Million	-191,884 Reduced 8.82%	1,982,841 $16.4 Million
Q3 2022 Nov 14, 2022	SELL	$2.94 - $11.87 $482,354 - $1.95 Million	-164,066 Reduced 7.01%	2,174,725 $16.7 Million
Q2 2022 Aug 15, 2022	SELL	$2.13 - $5.38 $481,179 - $1.22 Million	-225,906 Reduced 8.81%	2,338,791 $6.67 Million
Q1 2022 May 16, 2022	BUY	$4.38 - $18.78 $3.61 Million - $15.5 Million	825,057 Added 47.43%	2,564,697 $12.8 Million
Q4 2021 Feb 14, 2022	BUY	$19.0 - $30.95 $188,214 - $306,590	9,906 Added 0.57%	1,739,640 $34.2 Million
Q3 2021 Nov 16, 2021	BUY	$29.44 - $43.74 $21.4 Million - $31.8 Million	727,103 Added 72.52%	1,729,734 $50.9 Million
Q2 2021 Aug 16, 2021	SELL	$38.07 - $56.17 $1.13 Million - $1.67 Million	-29,782 Reduced 2.88%	1,002,631 $42.5 Million
Q1 2021 May 17, 2021	SELL	$32.41 - $70.91 $9.2 Million - $20.1 Million	-283,764 Reduced 21.56%	1,032,413 $52.5 Million
Q4 2020 Feb 16, 2021	BUY	$31.02 - $35.16 $40.8 Million - $46.3 Million	1,316,177 New	1,316,177 $44.8 Million

17.3M

500

33.5K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $62.4M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.